Health experts have warned against underestimating the risks of "indolent tumors" as China observes its 30th "National ...

The turning point came when Suki received a diagnosis that shed light on her mysterious symptoms: indolent systemic mastocytosis (ISM). ISM is a rare disease, estimated to occur in approximately 1 ...

Jill Zinsmeyer came to Austin for love, but Austin didn't love her. Living in Napa Valley, Calif., before the move, Zinsmeyer ...

Among more than 1,300 patients diagnosed with HCC, the median survival reached 37 months for those with screening-detected ...

Blueprint boosts Ayvakit peak sales estimate to $2B as key rare disease expansion accelerates Meanwhile, Blueprint these days ...

Harvard’s endowment is currently $50.7 billion. That means that the first year, the state would extract about $1.25 billion ...

Purpose. The pharmacology, efficacy, safety, and dosage and administration of bendamustine and its use in indolent non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) are reviewed.

Blueprint Medicines Corporation (Nasdaq: BPMC) today reported financial results, provided a business update for the first ...

Q1 2024 Earnings Call May 2, 2024 Blueprint Medicines Corporation misses on earnings expectations. Reported EPS is $ EPS, expectations were $-1.64. Blueprint Medicines Corporation isn’t one of the 30 ...

HAMPTON ROADS, Va. — Hematologist and Oncologist Dr. Pankit Vachhani and Suki Tipp, a woman living with Indolent Systemic Mastocytosis, join Coast Live to discuss the debilitating disease ...

This is an open-label trial in which 100 patients with rituximab-refractory indolent B-cell NHL were treated bendamustine 120 mg/m 2 on days 1 and 2 of every 21-day cycle for six to eight cycles.

My name is Towanda, and I will be your operator today. As a reminder, this call is being recorded for replay purposes. I ...